McKesson (MCK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Jun, 2026Voting matters and shareholder proposals
Shareholders are asked to elect eleven directors for a one-year term at the annual meeting.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2027 is on the agenda.
An advisory vote to approve executive compensation (say-on-pay) is included.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Eleven nominees are recommended for election to the board, including individuals with diverse backgrounds and expertise.
Executive compensation and say-on-pay
An advisory vote is scheduled for shareholders to approve the company's executive compensation program.
Partial view of Summaries dataset, powered by Quartr API
Latest events from McKesson
- Adjusted EPS up 20% and revenue up 8%, with strong Oncology & Multispecialty growth.MCK
Q1 2027 - Proxy statement covers annual meeting proposals, board governance, and voting rights.MCK
Proxy filing - Proxy details strong financials, board refreshment, and robust pay-for-performance alignment.MCK
Proxy filing - Specialty drugs, biosimilars, and automation drive growth and margin expansion into 2027.MCK
Bank of America Global Healthcare Conference 2026 - FY26 delivered double-digit revenue and EPS growth, with robust FY27 outlook and portfolio optimization.MCK
Q4 2026 - Revenue up 11%, adjusted EPS up 16%, and fiscal 2026 EPS guidance raised to $38.80–$39.20.MCK
Q3 2026 - Raised FY26 EPS guidance, specialty growth, and segment separation drive long-term value.MCK
Investor Day 2025 - Revenue up 21%, Adjusted EPS up 13%, 2025 guidance raised, $2.2B returned to shareholders.MCK
Q2 2025 - Adjusted EPS up 8% on 6% revenue growth; guidance, dividend, and buyback all raised.MCK
Q1 2025